The American Society for Radiation Oncology (ASTRO) announced that it plans to partner with CancerLinQ, a subsidiary of the American Society of Clinical Oncology (ASCO).
ASTRO will help ensure that CancerLinQ captures relevant patient data, and it will use findings from CancerLinQ Discovery to improve the care of patients undergoing radiation therapy. CancerLinQ Discovery is a clinical dataset platform that includes more than 1.5 million patient records from more than 70 oncology practices.
As an official partner, ASTRO will also encourage participation in CancerLinQ and facilitate data integration between oncology electronic health systems, the society said. It will also become a founding member of the CancerLinQ Oncology Leadership Council.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
